Special Issue

Aptamer-Based Targeted Conjugates for Diagnostic and Therapeutic Applications

Message from the Guest Editors

The mainstay of a therapeutic intervention is to specifically target diseased cells or tissues at high accuracy with low frequency of adverse side effects. One possibility to reach this goal is to use diseasespecific ligands as delivery agents to drive therapeutic cargos to the diseased sites while sparing the healthy ones. Oligonucleotide aptamers, analogously to protein antibodies, interact tightly with their targets because of their complex shapes, thus representing a useful class of molecular recognition probes in various diagnostic and therapeutic applications. The quick chemical production, design flexibility, and versatile chemical modification that allow different conjugation chemistries renders aptamers ideal targeting moieties in advanced targeted delivery strategies. Antibody-based targeted therapeutics provide high target specificity and affinity. The present Special Issue will include original research articles and review articles aimed at covering new synthetic methodologies of aptamer conjugates as well as their novel applications.

Guest Editors

Dr. Laura Cerchia

Institute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), National Research Council (CNR), Naples, Italy

Dr. Simona Camorani

Institute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), National Research Council (CNR), Naples, Italy

Deadline for manuscript submissions

closed (10 November 2021)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 4.9 CiteScore 7.9 Indexed in PubMed



mdpi.com/si/37883

Pharmaceutics MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 pharmaceutics@mdpi.com

mdpi.com/journal/ pharmaceutics





an Open Access Journal by MDPI

Impact Factor 4.9 CiteScore 7.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).

